CAS 658052-09-6
:Mapatumumab
Description:
Mapatumumab is a monoclonal antibody that targets the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 1 (also known as DR4). It is designed to induce apoptosis in cancer cells by activating the TRAIL signaling pathway, which is a mechanism that can selectively trigger cell death in malignant cells while sparing normal cells. This characteristic makes Mapatumumab a potential therapeutic agent in oncology, particularly for tumors that express the TRAIL receptors. The substance is typically administered via intravenous infusion and has been investigated in clinical trials for various malignancies, including solid tumors and hematological cancers. As a monoclonal antibody, Mapatumumab is produced using recombinant DNA technology, ensuring a high degree of specificity and affinity for its target. Its development reflects the growing trend in cancer therapy towards targeted treatments that minimize damage to healthy tissues while maximizing therapeutic efficacy against cancer cells. However, like all therapeutic agents, its use may be associated with specific side effects and requires careful monitoring during treatment.
Formula:Unspecified
Synonyms:- TRAIL-R 1mAb
- Immunoglobulin G1, anti-(human TRAIL-R1) (human monoclonal TRM-1 heavy chain), disulfide with human monoclonal TRM-1 λ-chain, dimer
- Immunoglobulin G1, anti-(human cytokine receptor DR4 (death receptor 4)) (human monoclonal TRM-1 heavy chain), disulfide with human monoclonal TRM-1 λ-chain, dimer
- Mapatumumab
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 2 products.
Mapatumumab
CAS:Mapatumumab (HGS-ETR1) is a agonistic monoclonal antibody against TNF-related apoptosis-inducing ligand receptor 1, with anti-cancer activity.Purity:>95%Color and Shape:LiquidMapatumumab
CAS:A fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1).
